Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium breve BX-18
- Development stage
- Discontinued
- Lead developer
- Takeda
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium breve BX-18 (also known as DSM 29508) is a specific strain of the probiotic bacterium *Bifidobacterium breve* that was developed by Baxalta (now part of Takeda) as a live biotherapeutic product (LBP). The strain was primarily investigated for the treatment of atopic dermatitis and other allergic conditions. BX-18 works by modulating the host immune system, specifically by suppressing Th2-mediated inflammatory responses (reducing cytokines like IL-4 and IL-13) and promoting a balanced Th1/Th2 environment, potentially through the induction of regulatory T cells (Tregs). Although patented for therapeutic use, the program does not appear in current clinical pipelines and is considered discontinued or not pursued beyond preclinical stages.
- Other names
- bifidobacterium brevis BX-18Bifidobacterium breve DSM 29508BX-18BX18BX 18
Beyond the preview
Go deeper on bifidobacterium breve BX-18.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium breve BX-18.